

Resource Summary Report

Generated by [dkNET](#) on Aug 18, 2026

Recombinant Anti-Granzyme B antibody [EPR20129-217]

RRID:AB_2924920

Type: Antibody

Proper Citation

Abcam Cat# ab208586, RRID:AB_2924920

Antibody Information

URL: http://antibodyregistry.org/AB_2924920

Proper Citation: Abcam Cat# ab208586, RRID:AB_2924920

Target Antigen: Granzyme B

Host Organism: rabbit

Clonality: recombinant monoclonal

Comments: Applications: WB, IHC-P, mIHC

Antibody Name: Recombinant Anti-Granzyme B antibody [EPR20129-217]

Description: This recombinant monoclonal targets Granzyme B

Target Organism: human

Clone ID: EPR20129-217

Antibody ID: AB_2924920

Vendor: Abcam

Catalog Number: ab208586

Record Creation Time: 20250820T014912+0000

Record Last Update: 20250820T115708+0000

Ratings and Alerts

No rating or validation information has been found for Recombinant Anti-Granzyme B antibody [EPR20129-217].

No alerts have been found for Recombinant Anti-Granzyme B antibody [EPR20129-217].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Zhou X, et al. (2026) Single-cell profiling unveils an exhaustion trajectory of ZNF683hi tissue-resident alveolar CD8+ T cells in checkpoint inhibitor pneumonitis. *Med (New York, N.Y.)*, 7(7), 101180.

Lopez-Lago MA, et al. (2026) Loss of tumor suppressor NF2 mediates resistance to CAR T cell and anti-PD-1 therapy: Strategies to restore immunotherapy sensitivity. *Med (New York, N.Y.)*, 7(7), 101149.

Cakmak P, et al. (2025) Spatial immune profiling defines a subset of human gliomas with functional tertiary lymphoid structures. *Immunity*, 58(11), 2847.

Luo B, et al. (2025) Resveratrol amplifies the anti-tumor effect of ?-PD-1 by altering the intestinal microbiome and PGD2 content. *Gut microbes*, 17(1), 2447821.

Felices M, et al. (2023) Reverse Translation Identifies the Synergistic Role of Immune Checkpoint Blockade and IL15 to Enhance Immunotherapy of Ovarian Cancer. *Cancer immunology research*, 11(5), 674.

Ma X, et al. (2023) Targeting TCF19 sensitizes MSI endometrial cancer to anti-PD-1 therapy by alleviating CD8+ T cell exhaustion via TRIM14-IFN-? axis. *Cell reports*, 42(8), 112944.